Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

re: Contracts

7 Apr 2005 07:00

Marchpole Holdings PLC07 April 2005 07 April 2005 Marchpole Holdings plc ("the Company") MARCHPOLE CONTINUES TO EXPAND CASTELBAJAC Marchpole Holdings plc, which designs, produces and sells high quality clothingand accessories for six world class brands (Yves Saint Laurent, Boateng,Jean-Charles de Castelbajac ('JCC'), Rossignol, Emanuel Ungaro and Ungaro), ispleased to announce that three significant contracts for their Jean Charles deCastelbajac ("JCC") business have been agreed. Extended Agreement with Itochu for Japan The Company is pleased to announce that its design agreement with Itochu hasbeen extended for a further six years from 2005 to 2011. Itochu manufacture, wholesale and retail Castelbajac collections for theJapanese market place with sales at wholesale prices for 2004 over €25 million.As part of this new agreement the design fee on these sales will be increasedfrom the current rate of 1.7% to 2.5% from October 2005. Sales for 2005 areexpected to reach €30 million. Castelbajac and Rossignol Launch New Collection Jean Charles de Castelbajac designed and launched his first Skiwear collectionfor the Autumn Winter 2002 season in collaboration with the world's number oneskiwear brand Rossignol. Over the course of the last two years sales haveincreased from €0.5 million to €3.2 million for Autumn Winter 2004 and sales forAutumn Winter 2005 are forecast to be €3.7 million. This is the fastest growingbusiness line within the Rossignol group. Following this success, Rossignol have asked Jean Charles to design and launch anew collection for the Summer. This new collection is aimed at the TrekkingOutdoor market. Launching in the Spring Summer 2006 season, the new agreement is for 5 years,with minimum guaranteed royalties over the period totalling €325,000. Castelbajac Glasses and Sunglasses The company has also signed an agreement with Codir SA to launch Castelbajaceyewear across Europe. Codir SA are the leader in market share with more than2700 retail outlets and sales of over €700 million. The contract is for 3 years, launching in Spring Summer 2005 with minimumguaranteed royalties for the period of €230,000. Commenting today, Chief Executive Greg Tufnell said : "Marchpole acquired the Castelbajac business in 2004 with the aim of creating astrong worldwide brand under its ownership. These new contracts, and thesignificant marketing contribution from the licensees, clearly demonstrate ourability to transform and grow this brand. We are successfully increasing ourpresence across a wide assortment of product categories and establishing thebrand in both Asia and Europe" For further information contact: Marchpole Greg Tufnell - Chief Executive 020 7908 7700 Michael Morris - Executive Director Shore Capital Alex Borrelli 020 7408 4090 Buchanan Tim Thompson / Nicola Cronk 020 7466 5000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSExercise of Options
23rd Jul 20187:00 amRNSNotice of Interim Results
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.